TCGA-97-7938-01A-11R-2170-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.550
- TNFA_SIGNALING_VIA_NFKB+0.480
- UV_RESPONSE_DN+0.430
- PROTEIN_SECRETION+0.420
- ANDROGEN_RESPONSE+0.360
- ESTROGEN_RESPONSE_EARLY+0.210
- HEDGEHOG_SIGNALING+0.190
- HEME_METABOLISM+0.190
- BILE_ACID_METABOLISM+0.180
- INFLAMMATORY_RESPONSE+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- E2F_TARGETS-0.570
- G2M_CHECKPOINT-0.520
- DNA_REPAIR-0.400
- MYC_TARGETS_V1-0.390
- OXIDATIVE_PHOSPHORYLATION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
- MTORC1_SIGNALING-0.320
- GLYCOLYSIS-0.280
- INTERFERON_ALPHA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-97-7546-01A-11R-2039-07 | — | cohortA1 | 0.859 |
| 2 | TCGA-AR-A24W-01A-11R-A169-07 | — | A | 0.837 |
| 3 | TCGA-55-7284-01B-11R-2241-07 | — | cohortA1 | 0.829 |
| 4 | TCGA-55-6543-01A-11R-1755-07 | — | cohortA1 | 0.823 |
| 5 | TCGA-A2-A1G0-01A-11R-A13Q-07 | — | A | 0.814 |
| 6 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.799 |
| 7 | SRR6013574 | — | cohortA1 | 0.798 |
| 8 | MNG438 | — | — | 0.797 |
| 9 | TCGA-75-6206-01A-11R-1755-07 | — | cohortA2 | 0.796 |
| 10 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |